Vesicare® (solifenacin succinate) Now Available Nationwide in US
A New Option for Men and Women Suffering from Overactive Bladder Symptoms
OAB is a medical condition that causes the bladder muscle (known as the detrusor muscle) to contract while the bladder is filling with urine, rather than when the bladder is full. This results in a patient experiencing urgency (an immediate and strong sense to urinate), frequency (the need to frequently go to the bathroom), and for many, urge incontinence (an involuntary loss of urine).
Vesicare was approved by the U.S. Food and Drug Administration (FDA) in November 2004, and was found to significantly reduce the number of incontinence episodes for patients over 12-weeks. In clinical studies involving more than 3,000 patients with symptoms of urgency, frequency and/or urge incontinence, once-daily Vesicare 5 mg and 10 mg showed statistically and clinically significant improvement in all major symptoms of OAB during a 12-week study period.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.